BioSpace News Archive

Oncopeptides AB announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that have received 2-4 prior lines of therapy, have been published in the Lancet Hematology.

Bioretec Ltd, a globally operating Finnish medical device company and a pioneer in bioresorbable orthopedic implants, has entered into a raw material supply agreement with Meotec GmbH, a German manufacturer of implantable materials.

Spago Nanomedical AB announced that interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix is well tolerated and provides clear contrast enhancement in MRI images of solid tumors in the breast, as well as in the pancreas and liver.

ADVANZ PHARMA Corp. Limited and Allecra Therapeutics announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway.

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has been granted a European Patent for compositions and methods for treating travelers’ diarrhea.

Insightful Science, the software company enabling the Cloud for Scientific Discovery, announced today that it has acquired Omiq Inc, a company specialized in data science SaaS solutions for high dimensional flow cytometry and quantitative multi-omics data.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the company’s attendance at the 27th Annual AF Symposium.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will present at the Sidoti Winter Virtual Investor Conference.

Imcyse today reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the Company’s lead candidate IMCY-0098, a proinsulin-derived ImotopeTM engineered to treat and prevent T1D.

First Wave BioPharma, Inc., today provided an update on its adrulipase (FW-EPI) clinical program and advances involving adrulipase.